It has been a long-term concern for Alexion Pharma's shareholders that they are not being rewarded adequately. The recent performance of the company's stock, in relation to earnings, validates their worry. So, what is in store for the stakeholders even as the COVID uncertainty refuses to ease!
a company run by idiots! They should go back to primary care because they have no idea what they are doing
